Strategic Financial Concepts LLC purchased a new stake in shares of Mesoblast Limited (NASDAQ:MESO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 138,600 shares of the company's stock, valued at approximately $2,744,000. Strategic Financial Concepts LLC owned 0.12% of Mesoblast at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of MESO. Jane Street Group LLC grew its holdings in shares of Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock valued at $695,000 after buying an additional 26,959 shares during the last quarter. XY Capital Ltd bought a new position in Mesoblast in the 3rd quarter valued at approximately $244,000. Creative Planning purchased a new stake in Mesoblast during the 3rd quarter valued at $147,000. Clayton Financial Group LLC bought a new stake in shares of Mesoblast in the 4th quarter worth $275,000. Finally, Ballentine Partners LLC purchased a new position in shares of Mesoblast in the fourth quarter worth $222,000. Institutional investors own 1.43% of the company's stock.
Mesoblast Stock Down 0.6 %
MESO stock traded down $0.11 during midday trading on Thursday, reaching $18.43. 159,865 shares of the company's stock traded hands, compared to its average volume of 409,795. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast Limited has a 52-week low of $1.83 and a 52-week high of $22.00. The stock's 50-day moving average is $16.89 and its 200 day moving average is $11.25.
Wall Street Analysts Forecast Growth
MESO has been the topic of a number of recent analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Jefferies Financial Group downgraded shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday, December 23rd. Finally, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.
Read Our Latest Analysis on Mesoblast
Mesoblast Profile
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
